Medscape (9/6, Jenkins) reports that researchers found “no increased risk for Alzheimer’s disease following treatment with androgen deprivation therapy (ADT) in a group of men age 67 years and older with advanced prostate cancer.” The research was published online in the Journal of Clinical Oncology. This “finding contrasts with recent reports suggesting that there is an increased risk for cognitive impairment in patients who receive ADT.”
Related Links:
— Medscape (requires login and subscription)